We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

N-Acetyl Cysteine in Trichotillomania

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00354770
First Posted: July 20, 2006
Last Update Posted: December 16, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jon Grant, University of Chicago
Results First Submitted: March 1, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Trichotillomania
Interventions: Drug: Placebo
Drug: N-Acetyl Cysteine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
N-Acetyl Cysteine N-Acetyl Cysteine (NAC) - 1200mg-2400mg by mouth per day
Placebo Placebo pills

Participant Flow:   Overall Study
    N-Acetyl Cysteine   Placebo
STARTED   25   25 
COMPLETED   22   22 
NOT COMPLETED   3   3 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
N-Acetyl Cysteine N-Acetyl Cysteine (NAC) - 1200mg-2400mg by mouth per day
Placebo Placebo pills
Total Total of all reporting groups

Baseline Measures
   N-Acetyl Cysteine   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 25   25   50 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      25 100.0%      25 100.0%      50 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Age 
[Units: Years]
Mean (Standard Deviation)
 35.8  (13.6)   32.7  (10.5)   34.5  (11.5) 
Gender 
[Units: Participants]
Count of Participants
     
Female      24  96.0%      21  84.0%      45  90.0% 
Male      1   4.0%      4  16.0%      5  10.0% 
Region of Enrollment 
[Units: Participants]
     
United States   25   25   50 


  Outcome Measures

1.  Primary:   Massachusetts General Hospital Hairpulling Scale   [ Time Frame: Baseline and final visit after 12 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Jon E. Grant
Organization: University of Chicago
phone: 773-834-1325
e-mail: jongrant@uchicago.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Jon Grant, University of Chicago
ClinicalTrials.gov Identifier: NCT00354770     History of Changes
Other Study ID Numbers: 0604M85110
First Submitted: July 18, 2006
First Posted: July 20, 2006
Results First Submitted: March 1, 2012
Results First Posted: January 15, 2014
Last Update Posted: December 16, 2016